Distigmine
- TRADE NAME: Ubretid (Sanofi)
- INDICATIONS: Post-operative urinary retention, post operative ileus and intestinal atony, adjunct in the treatment of myasthenia gravis.
- CLASS: Acetylcholine inhibitor
- HALF-LIFE: N/A
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Beta blockers, Local anesthetics, Muscle relaxants
PREGNANCY CATEGORY: C
Please login to see the rest of this drug profile
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric